Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD The Liver Meeting® 2024 to Support the Ongoing Phase 1/2 Study for RTX001 in End-Stage Liver Disease.
– Complete 3-year clinical data from the MATCH Phase 2 study demonstrate long-term efficacy and safety with autologous, non-engineered macrophages in patients with advanced liver cirrhosis.
– New preclinical data support superior anti-inflammatory and anti-fibrotic effect of RTX001, an engineered macrophage investigational therapy, compared to non-engineered macrophages.
– RTX001 has recently entered into a Phase 1/2 interventional study in end-stage liver disease.
Edinburgh and London, UK, 11 November 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company spun out of the University of Edinburgh pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases, today announces new clinical and preclinical data highlighting the anti-inflammatory and anti-fibrotic effect of regenerative macrophage therapy. The data will be presented in oral and poster presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024, which is being held in San Diego, California from 15-19 November 2024.
